Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2011

01-10-2011

Antibiotic Therapy in Neonatal and Pediatric Septic Shock

Authors: Rajesh K. Aneja, Ruby Varughese-Aneja, Carol G. Vetterly, Joseph A. Carcillo

Published in: Current Infectious Disease Reports | Issue 5/2011

Login to get access

Abstract

Severe sepsis accounts for nearly 4,500 deaths (mortality rate 10%), and is responsible for nearly $2 billion annual healthcare expenditure in the United States. Early and speedy treatment of critically ill septic patients can halt or reduce the likelihood of physiologic progression to multi-system organ failure. A cornerstone of this therapeutic strategy is antibiotic administration. In this review, we discuss the empirical treatment strategies for the treatment of early and late neonatal sepsis, along with pediatric sepsis. Furthermore, we discuss the rationale that underlies the adoption of such treatment strategies. The present article also discusses the emergence of multi-drug organisms as the causative agents for sepsis, i.e. methicillin-resistant Staphylococcus aureus (MRSA), resistant enterococci and Klebsiella pneumoniae carbapenemases (KPC).
Literature
1.
Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med. 2005;6(3 Suppl):S3–5.PubMedCrossRef
2.
Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167(5):695–701.PubMedCrossRef
3.
Hartman M, Clermont G, Angus D, Watson R. Pediatric severe sepsis in the US: 1995 vs. 2005. Crit Care Med. 2008;36:A76.
4.
Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167(5):695–701.PubMedCrossRef
5.
•• Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666–88. A must read for all pediatricians, as these are the guidelines for pediatric and neonatal septic shock.PubMedCrossRef
6.
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–96. An important article that highlights the role of timely administration of antibiotics. PubMedCrossRef
7.
Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38(4):1045–53.PubMedCrossRef
8.
Muller-Pebody B, Johnson AP, Heath PT, et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F4–8.PubMedCrossRef
9.
Rao SC, Ahmed M, Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2006;(1):CD005091.
10.
Edwards M, Baker C. In: Long S, Pickering L, Prober C, editors. Bacterial infections in the neonate. Philadelphia: Churchill Livingstone; 2002.
11.
• Vergnano S, Menson E, Kennea N, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F9–14. This is a prospective multi-center surveillance study that was conducted in 12 English neonatal units. PubMedCrossRef
12.
Bryan CS, John Jr JF, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child. 1985;139(11):1086–9.PubMed
13.
de Man P, Verhoeven BA, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355(9208):973–8.PubMedCrossRef
14.
Modi N, Damjanovic V, Cooke RW. Outbreak of cephalosporin resistant Enterobacter cloacae infection in a neonatal intensive care unit. Arch Dis Child. 1987;62(2):148–51.PubMedCrossRef
15.
Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics. 2006;117(1):67–74.PubMedCrossRef
16.
Auriti C, Maccallini A, Di Liso G, et al. Risk factors for nosocomial infections in a neonatal intensive-care unit. J Hosp Infect. 2003;53(1):25–30.PubMedCrossRef
17.
Orsi G, d’Ettorre G, Panero A, et al. Hospital-acquired infection surveillance in a neonatal intensive care unit. Am J Infect Control. 2009;37:201–3.PubMedCrossRef
18.
Tan T, Mason E, Ou C, Kaplan S. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother. 1993;37:2401–6.PubMed
19.
Wu J, Chen C, Tsao P, et al. Neonatal sepsis: a 6-year analysis in a neonatal care unit in Taiwan. Pediatr Neonatol. 2009;50:88–95.PubMedCrossRef
20.
Khashu M, Osiovich H, Henry D, et al. Persistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit. Pediatrics. 2006;117(2):340–8.PubMedCrossRef
21.
Archer GL, Tenenbaum MJ, Haywood 3rd HB. Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices. JAMA. 1978;240(8):751–3.PubMedCrossRef
22.
Auger P, Laaban JP, Gagnon G, et al. Rifampin therapy for Staphylococcus epidermidis endocarditis. Can Med Assoc J. 1982;127(7):609–10.PubMed
23.
Chamovitz B, Bryant RE, Gilbert DN, Hartstein AI. Prosthetic valve endocarditis caused by Staphylococcus epidermidis. Development of rifampin resistance during vancomycin and rifampin therapy. JAMA. 1985;253(19):2867–8.PubMedCrossRef
24.
Isaacs D. A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units. Arch Dis Child Fetal Neonatal Ed. 2003;88(2):F89–93.PubMedCrossRef
25.
Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988–1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000;106(6):1387–90.PubMedCrossRef
26.
Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285–91.PubMedCrossRef
27.
Gordon A, Isaacs D. Late onset neonatal Gram-negative bacillary infection in Australia and New Zealand: 1992–2002. Pediatr Infect Dis J. 2006;25(1):25–9.PubMedCrossRef
28.
Kutko MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med. 2003;4(3):333–7.PubMedCrossRef
29.
Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children’s Hospital. Arch Pediatr Adolesc Med. 2005;159(10):980–5.PubMedCrossRef
30.
Ochoa TJ, Mohr J, Wanger A, et al. Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis. 2005;11(6):966–8.PubMed
31.
Smith JM, Cook GM. A decade of community MRSA in New Zealand. Epidemiol Infect. 2005;133(5):899–904.PubMedCrossRef
32.
Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–74.PubMedCrossRef
33.
Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest. 2006;87(1):3–9.PubMedCrossRef
34.
Panton P, Came M, Valentine F. Staphylococcal toxin. Lancet. 1932;1:506–8.CrossRef
35.
Prevost G, Cribier B, Couppie P, et al. Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun. 1995;63(10):4121–9.PubMed
36.
Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001–2003. Pediatr Infect Dis J. 2006;25(4):343–8.PubMedCrossRef
37.
Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753–9.PubMedCrossRef
38.
Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005;353(12):1245–51.PubMedCrossRef
39.
Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis. 2003;37(8):1050–8.PubMedCrossRef
40.
Gillet Y, Etienne J, Lina G, Vandenesch F. Association of necrotizing pneumonia with Panton-Valentine leukocidin-producing Staphylococcus aureus, regardless of methicillin resistance. Clin Infect Dis. 2008;47(7):985–6.PubMedCrossRef
41.
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.PubMedCrossRef
42.
Martinez-Aguilar G, Hammerman WA, Mason Jr EO, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003;22(7):593–8.PubMed
43.
Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2003;22(9 Suppl):S178–85.PubMed
44.
Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis. 2005;37(2):153–4.PubMedCrossRef
45.
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–85.
46.
47.
Fraimow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin. 2011;27(1):163–205.PubMedCrossRef
48.
Sullivan J, Tobias JD. Preliminary experience with the use of oral linezolid in infants for the completion of antibiotic therapy in the outpatient setting after admission to the pediatric intensive care unit. Am J Ther. 2006;13(6):473–7.PubMed
49.
Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–9.PubMedCrossRef
50.
Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151–61.PubMedCrossRef
51.
Maltezou HC, Giakkoupi P, Maragos A, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect. 2009;58(3):213–9.PubMedCrossRef
52.
Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56(1):128–32.PubMedCrossRef
53.
•• Overturf GD. Carbapenemases: a brief review for pediatric infectious disease specialists. Pediatr Infect Dis J. 2010;29(1):68–70. An excellent review of Carbapenemases.PubMed
Metadata
Title
Antibiotic Therapy in Neonatal and Pediatric Septic Shock
Authors
Rajesh K. Aneja
Ruby Varughese-Aneja
Carol G. Vetterly
Joseph A. Carcillo
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-011-0197-5

Other articles of this Issue 5/2011

Current Infectious Disease Reports 5/2011 Go to the issue

ReviewPaper

What’s New in the Management of Bacterial Septic Arthritis?

ReviewPaper

When and How to Cover for Resistant Gram-Negative Bacilli in Severe Sepsis and Septic Shock

ReviewPaper

Advances in the Diagnosis and Management of Pediatric Osteomyelitis

ReviewPaper

When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock

ReviewPaper

Soft Tissue Infections Caused by Marine Bacterial Pathogens: Epidemiology, Diagnosis, and Management

ReviewPaper

Early and Adequate Antibiotic Therapy in the Treatment of Severe Sepsis and Septic Shock

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits